OGT expands CytoSure™ aCGH offering with high resolution Duchenne Muscular Dystrophy array
High probe density ensures increased confidence in detecting DMD gene gains and losses
By: David Robinson
OGT’s bioinformatics expertise together with extensive input from Emory Genetics Laboratory and the array manufacturing precision of Agilent Technologies ensures confidence in quality and performance. The CytoSure DMD array has undergone a process of empirical testing and optimisation to provide probe sets of extremely high sensitivity and specificity. Average exon probe spacing of 10 bp (106 bp within introns) ensures excellent resolution. As a result the entire DMD gene is covered on a single 44,000 feature array, which enables 4 full arrays per slide, maximising cost-efficiency by reducing the cost per sample.
John Anson, Research and Development Director at OGT, stated, “By combining Emory Genetics Laboratory and OGT’s expertise in microarray design we believe that we are bringing a powerful tool to the market that will improve our understanding of the deletions and duplications that can occur within the DMD gene. We hope that the CytoSure DMD array will contribute to a better understanding of the genetic basis of the muscular dystrophies and will ultimately lead to the development of new diagnostic tools and therapeutic approaches.”
The CytoSure DMD array adds to OGT’s comprehensive portfolio of products and services, which together provide a complete solution to running oligo aCGH in the laboratory, from set-up to result. Manual processing and analysis of the CytoSure DMD array is straightforward using the CytoSure DMD array, CytoSure Genomic DNA labelling kit and the comprehensive new CytoSure Interpret Software. For higher throughput applications, the CytoSure DMD array is fully compatible with SciGene workflow automation products (now distributed in Europe by OGT).
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park,
Sandy Lane, Yarnton, Oxford OX5 1PF
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: firstname.lastname@example.org
About Oxford Gene Technology
Founded in 1995 by Professor Ed Southern, OGT has a proven pedigree in microarray technology and services. Our mission is to advance molecular medicine through pioneering discovery and application of molecular technologies. OGT’s key focus areas are: high throughput genomic services and biomarker discovery, cytogenetics, single cell analysis, and licensing.
OGT’s genomic services (Genefficiency™)
OGT’s products and services for cytogenetics (CytoSure™) include a range of high resolution oligonucleotide arrays, labelling kits and interpretation software that together provide a complete solution for the detection of chromosomal abnormalities.
Duchenne muscular dystrophy (DMD) is an X-linked (Xp21) condition caused by mutations in the DMD gene. It is a relatively common disease affecting an estimated 1 in 3,500 male births and is characterised by progressive muscle degeneration. The DMD gene is one of the largest genes in the human genome (2.2 Mb). Deletions and duplications within the DMD gene lead to muscular dystrophies (MD) and make up 60-70% of cases of Duchenne MD. Until now, it has been difficult to accurately detect and size deletions and duplications within the DMD gene using currently available non-array methods, which do not offer sufficiently high resolution.
The CytoSure DMD array is not available for sale in the U.S.A
# # #
Established in 2002, We’re marketers with a solid science foundation specialising in scientific and healthcare marketing. We put together campaigns to suit our clients’ requirements such as PR to a fully integrated campaign.